申请人:Bradley Paul Anthony
公开号:US20090099209A1
公开(公告)日:2009-04-16
Compounds of formula (I),
or pharmaceutically acceptable derivatives thereof, wherein:
R
1
represents H, C
1-6
alkyl, C
1-6
alkyloxy, C
3-8
cycloalkyl, or halo;
R
2
represents H, C
1-6
alkyl (optionally substituted by R
3
), phenyl (optionally substituted by CN), or Het;
R
3
represents OH, CN, Het, —R
4
—C
1-6
alkyl, or CONR
5
R
6
;
R
4
represents —CO
2
—, or —O—;
R
5
and R
6
independently represent H, C
1-6
alkyl (optionally substituted by OR
7
) or C
3-8
cycloalkyl;
R
7
represents H or C
1-6
alkyl;
Het represents a five or six membered aromatic heterocyclic group containing (i) from one to four nitrogen heteroatom(s) or (ii) one or two nitrogen heteroatom(s) and one oxygen or one sulphur heteroatom or (iii) one or two oxygen or sulphur heteroatom(s), said heterocyclic group being optionally substituted by one or more groups selected from CN and C
1-6
alkyl;
R
8
represents C
1-6
alkyl, C
1-6
alkyloxy, C
3-8
cycloalkyl, or halo; and
R
9
and R
10
independently represent H, C
1-6
alkyl, C
1-6
alkyloxy, CN, CF
3
or halo;
may be useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.
式(I)的化合物或其药学上可接受的衍生物,其中:
R1代表氢、C1-6烷基、C1-6烷氧基、C3-8环烷基或卤素;
R2代表氢、C1-6烷基(可选地被R3取代)、苯基(可选地被CN取代)或Het;
R3代表OH、CN、Het、—R4—C1-6烷基或CONR5R6;
R4代表—CO2—或—O—;
R5和R6独立地代表氢、C1-6烷基(可选地被OR7取代)或C3-8环烷基;
R7代表氢或C1-6烷基;
Het代表一个含有(i)从一个到四个氮杂原子或(ii)一个或两个氮杂原子和一个氧或硫杂原子或(iii)一个或两个氧或硫杂原子的五元或六元芳香杂环基,该杂环基可选地被一个或多个从CN和C1-6烷基中选择的基团取代;
R8代表C1-6烷基、C1-6烷氧基、C3-8环烷基或卤素;
R9和R10独立地代表氢、C1-6烷基、C1-6烷氧基、CN、CF3或卤素;
这些化合物可能有助于治疗子宫内膜异位症、子宫肌瘤(平滑肌瘤)、月经过多、子宫内膜腺肌症、原发性和继发性痛经(包括性交疼痛、排便疼痛和慢性盆腔疼痛的症状)或慢性盆腔疼痛综合征。